-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S5ZGwfAS2u4OZBmFpPrNWi54F4i7n136nbFWlMMxc9DBlOZhn+0CoY13Y9Lv9/2i O4O5MGYf7FlwNO8mfWuzzg== 0000904454-00-000048.txt : 20000314 0000904454-00-000048.hdr.sgml : 20000314 ACCESSION NUMBER: 0000904454-00-000048 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000313 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CORVAS INTERNATIONAL INC CENTRAL INDEX KEY: 0000882100 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330238812 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-42011 FILM NUMBER: 567892 BUSINESS ADDRESS: STREET 1: 3030 SCIENCE PARK RD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194559800 MAIL ADDRESS: STREET 2: 3030 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INTERNATIONAL BIOTECHNOLOGY TRUST PLC CENTRAL INDEX KEY: 0000942257 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: FIVE ARROWS HOUSE STREET 2: ST SWITHINS LN CITY: LONDON EC4N 8NR MAIL ADDRESS: STREET 1: FIVE ARROWS HOUSE STREET 2: ST SWITHINS LN CITY: LONDON EC4N 8NR SC 13D/A 1 SC 13D/A CUSIP No. 221005 10 1 Page 1 of 5 Pages SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)[FN]1 Corvas International, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 221005 10 1 (CUSIP Number) Jeremy L. Curnock Cook John C. MacMurray, Esq. Rothschild Asset Management Ltd. Reboul, MacMurray, Hewitt, Five Arrows House Maynard & Kristol St. Swithin's Lane 45 Rockefeller Plaza London EC4N 8NR England New York, New York 10111 Tel. 011-171-280-5000 Tel. (212) 841-5700 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 16, 2000 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d- 1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. - -------- 1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 221005 10 1 Page 2 of 5 Pages 1) Name of Reporting Person International S.S. or I.R.S. Identification Biotechnology No. of Above Person Trust plc 2) Check the Appropriate Box (a) [ ] if a Member of a Group (b) [ ] 3) SEC Use Only 4) Source of Funds WC 5) Check if Disclosure of Legal Proceedings is Not Applicable Required Pursuant to Items 2(d) or 2(e) 6) Citizenship or Place of Organization United Kingdom Number of 7) Sole Voting 2,175,837 shares of Shares Beneficially Power Common Stock, $.001 Owned by par value ("Common Reporting Person Stock") 8) Shared Voting Power -0- 9) Sole Disposi- 2,175,837 shares of tive Power Common Stock 10) Shared Dis- positive Power -0- 11) Aggregate Amount Beneficially 2,175,837 shares of Owned by Each Reporting Person Common Stock 12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares 13) Percent of Class Represented by 12.44% Amount in Row (11) 14) Type of Reporting Person CO CUSIP No. 221005 10 1 Page 3 of 5 Pages Amendment No. 2 to Schedule 13D Reference is hereby made to the statement on Schedule 13D originally filed with the Securities and Exchange Commission on February 9, 1996, as amended by Amendment No.1 thereto filed with the Securities and Exchange Commission on September 24, 1999 (as amended, the "Schedule 13D"). Terms defined in the Schedule 13D are used herein as so defined. The Schedule 13D is hereby amended as follows: Item 3. Source and Amount of Funds or Other Consideration. Item 3 is hereby amended by adding the following thereto: This statement relates to the transactions by IBT in the shares of Common Stock of the Issuer consummated by IBT from the period February 1, 2000 through March 1, 2000, including the exercise by IBT on February 9, 2000 of warrants to purchase an aggregate 1,561,337 shares of Common Stock. The source of funds for such exercise was IBT's working capital, or funds available for investment. Item 5. Interest in Securities of the Issuer. Item 5 is hereby amended and restated to read in its entirety as follows: (a) Based on a total of 17,488,391 shares of Common Stock outstanding, IBT owns 2,175,837 shares of Common Stock, or approximately 12.44% of the Common Stock outstanding. (b) Except as described in Item 6 of the Schedule 13D, IBT has sole power to vote or direct the voting of and to dispose or to direct the disposition of the shares of Common Stock referred to in paragraph (a) above. (c) Except as set forth in Item 3 above and as set forth below, neither IBT nor any of the persons identified in Item 2 above has effected any transaction in the Common Stock in the past 60 days. In addition to the exercise of the warrants, the following transactions were effected by IBT: On February 14, 2000, IBT sold an aggregate 90,000 shares of Common Stock on the open market at a per share price of $13.94. On February 15, 2000, IBT sold an aggregate 30,000 shares of Common Stock on the open market at a per share price of $14.75. CUSIP No. 221005 10 1 Page 4 of 5 Pages On February 16, 2000, IBT sold an aggregate 95,000 shares of Common Stock on the open market at a per share price of $14.85. On February 17, 2000, IBT sold an aggregate 123,000 shares of Common Stock on the open market at a per share price of $ 15.50. On February 18, 2000, IBT sold an aggregate 119,500 shares of Common Stock on the open market at a per share price of $15.98. On February 22, 2000, IBT sold an aggregate 18,000 shares of Common Stock on the open market at a per share price of $14.94. On February 23, 2000, IBT sold an aggregate 20,000 shares of Common Stock on the open market at a per share price of $13.70. On February 24, 2000, IBT sold an aggregate 70,000 shares of Common Stock on the open market at a per share price of $13.60. On February 25, 2000, IBT sold an aggregate 30,000 shares of Common Stock on the open market at a per share price of $14.29. On February 28, 2000, IBT sold an aggregate 120,000 shares of Common Stock on the open market at a per share price of $12.17. On February 29, 2000, IBT sold an aggregate 120,000 shares of Common Stock on the open market at a per share price of $12.30. On March 1, 2000, IBT sold an aggregate 250,000 shares of Common Stock on the open market at a per share price of $16.30. (d) No other person has the power to direct the receipt of dividends on, or the proceeds from sales of, the shares of Common Stock owned by IBT. (e) Not applicable. CUSIP No. 221005 10 1 Page 5 of 5 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 8, 2000 INTERNATIONAL BIOTECHNOLOGY TRUST PLC By: /s/Jeremy L. Curnock Cook Director -----END PRIVACY-ENHANCED MESSAGE-----